Get the Stockscreener App
9.05
5.97%
0.51
After Hours:
9.05
Emergent Biosolutions Inc stock is traded at $9.05, with a volume of 1.34M.
It is up +5.97% in the last 24 hours and up +9.96% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
See More
Previous Close:
$8.54
Open:
$8.69
24h Volume:
1.34M
Relative Volume:
1.57
Market Cap:
$466.95M
Revenue:
$676.80M
Net Income/Loss:
$-8.60M
P/E Ratio:
-31.99
EPS:
-0.2829
Net Cash Flow:
$135.40M
1W Performance:
+9.96%
1M Performance:
+9.96%
6M Performance:
-12.48%
1Y Performance:
+82.83%
1-Day Range:
$8.67
$9.5401
1-Week Range:
$7.5318
$9.5401
52-Week Range:
$4.71
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
9.05 | 440.63M | 676.80M | -8.60M | 135.40M | -0.2829 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
SAB Biotherapeutics and Emergent BioSolutions Sign Manufacturing and Supply Agreement for Drug Product Development - Minichart
Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013 - AOL.com
Emergent BioSolutions director Keith Katkin sells $128,182 in stock By Investing.com - Investing.com Australia
Singapore approves Emergent's ACAM2000 for high-risk mpox use - Stock Titan
Emergent BioSolutions director DeGolyer sells $129,993 in shares By Investing.com - Investing.com India
Emergent BioSolutions director Dayal sells $115,610 in stock - Investing.com
Emergent BioSolutions director DeGolyer sells $129,993 in shares - Investing.com
Emergent BioSolutions director Keith Katkin sells $128,182 in stock - Investing.com
Emergent BioSolutions (NYSE: EBS) director nets stock awards, tax-driven share sales - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares and receives new grants - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares and receives RSUs, options - Stock Titan
Director Marvin White (NYSE: EBS) receives RSU and stock option awards - Stock Titan
Emergent BioSolutions (EBS) director granted RSUs and stock options for board service - Stock Titan
Director at Emergent BioSolutions (NYSE: EBS) receives RSU and option grants - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares, receives new awards - Stock Titan
Emergent BioSolutions (EBS) director granted RSUs and stock options in annual award - Stock Titan
Emergent BioSolutions (NYSE: EBS) chair granted RSUs and stock options as board pay - Stock Titan
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 - Bioscience Association Manitoba
H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - Moomoo
MSN Money - MSN
Emergent BioSolutions (EBS) Q1 EPS Profit Challenges Narrative Of Persistent Losses - Sahm
Emergent BioSolutions Earnings Call Highlights Turnaround Momentum - The Globe and Mail
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer LINDAHL RICHARD S - Moomoo
Emergent BioSolutions | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer PAPA JOSEPH C - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Perl Jessica - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Hartzel William - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Lowry Simon C - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Glessner Coleen - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Williams Paul Anthony - Moomoo
Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved - MarketBeat
Emergent BioSolutions Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:EBS) 2026-05-02 - Seeking Alpha
Emergent BioSolutions Q1 2026 Financial Results: Earnings, Revenue, and Key Risk Factors Explained - Minichart
Emergent BioSolutions Posts Weak Q1 Results Amid Turnaround - The Globe and Mail
Emergent BioSolutions (EBS) SVP awarded 100,111 restricted stock units under amended plan - Stock Titan
Emergent BioSolutions (EBS) awards 100,111 RSUs to R&D CMO - Stock Titan
Emergent BioSolutions (NYSE: EBS) awards 100,111 RSUs to EVP - Stock Titan
Emergent BioSolutions (EBS) CFO receives 162,680 restricted stock units - Stock Titan
Emergent BioSolutions (EBS) SVP awarded 104,282 restricted stock units - Stock Titan
SVP at Emergent BioSolutions (NYSE: EBS) receives 100,111 RSUs - Stock Titan
Emergent BioSolutions (NYSE: EBS) CEO gets 187,708 RSUs over 3 years - Stock Titan
[144] Emergent BioSolutions Inc. SEC Filing - Stock Titan
Emergent (EBS) Q1 2026 Earnings Transcript - The Globe and Mail
Emergent Biosolutions Q1 2026 earnings preview - MSN
Q1 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Emergent BioSolutions Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Emergent Biosolutions Q1 Earnings Call Highlights - MarketBeat
Emergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights - GuruFocus
Emergent BioSolutions Q1 2026 slides: revenue tops guidance amid turnaround - Investing.com Australia
Emergent Biosolutions (NYSE:EBS) Posts Quarterly Earnings Results, Beats Expectations By $0.46 EPS - MarketBeat
Emergent BioSolutions Q1 2026 slides: revenue tops guidance amid turnaround By Investing.com - Investing.com South Africa
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):